Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O15303
UPID:
GRM6_HUMAN
Alternative names:
-
Alternative UPACC:
O15303
Background:
Metabotropic glutamate receptor 6 (mGluR6) plays a pivotal role in visual perception. As a G-protein coupled receptor for glutamate, it is essential for normal vision by modulating adenylate cyclase activity and stimulating TRPM1 channel activity and Ca(2+) uptake.
Therapeutic significance:
The protein's involvement in congenital stationary night blindness type 1B highlights its therapeutic potential. Understanding the role of Metabotropic glutamate receptor 6 could open doors to potential therapeutic strategies for vision impairments.